Post hoc 10-year analysis of a phase 3 trial in 434 women with early triple-negative breast cancer: 1 year of metronomic capecitabine vs observation improved disease-free survival (78.1% vs 66.6%; HR 0.61); overall survival was not significantly different.
Secondary analysisn = 434 women
Yuan et al. Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial